Recruiting PHASE4 INTERVENTIONAL 1-arm
NCT07272512
Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms (ZSPAC-17)
Sponsor: Shanghai Zhongshan Hospital
Conditions
Neuroendocrine Neoplasms Neuroendocrine Tumors
Interventions
Surufatinib
Updated 1 time since 2026 Last updated: Dec 18, 2025 Started: Nov 11, 2025 Primary completion: Nov 29, 2027 Completion: Nov 29, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07272512, this PHASE4 trial focuses on Neuroendocrine Neoplasms and Neuroendocrine Tumors and remains actively recruiting participants. Sponsored by Shanghai Zhongshan Hospital, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai Zhongshan Hospital
Data source: Shanghai Zhongshan Hospital
For direct contact, visit the study record on ClinicalTrials.gov .